We did not detect differences in histopathological features within the tumor (Fig. 5B) but, the loss of CDKN2A/B in certain regions of the tumor could likely explain the rapid progression of the patient with a clinical diagnosis of diffuse astrocytoma IDH-mutant, WHO (2016) grade II. This evidence concerns the gene CDKN2A and diffuse astrocytoma.